Skip to content
AASLD Family of Websites: Liver Fellow Network
AASLD.org AASLD Foundation LiverLearning Career Center Journals The Liver Meeting HCV Guidelines
AASLD Logo
AASLD Logo

LFN Main Navigation

  • Topics
    Acute Liver Failure Alcohol-Associated Liver Disease Autoimmune Hepatitis Career Development and Mentorship Cholestatic Liver Disease Complications of Liver Disease and Portal Hypertension Drug-Induced Liver Disease HepMadness Inherited Disorders Liver Anatomy, Development, and Physiology Liver Infections Liver Physiology Liver Related Infections MASLD/MASH Neoplasms of the Liver Pathology Pediatrics Pregnancy-Related Liver Disease Symptoms and Clinical Presentation of Liver Disease and Portal HTN Systemic Conditions with Hepatic Manifestations Transplantation and Surgery Vascular Viral Hepatitis
  • Core Series
    Back to Basics Clinical Pearls Webinars Evidence Corner Pathology Pearls Podcast The Why? Series Tools of the Trade View All Core Series Practice Questions
  • Tweetorials
  • About

Posts by Melissa Kaltenbach

Melissa Kaltenbach

Melissa Kaltenbach

Content Writer

The Why? Series

Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease?

GLP-1 agonists are approved for the treatment of diabetes and for obesity. Why are patients with non-alcoholic fatty liver disease (NAFLD) suddenly being prescribed GLP-1 agonists and what are the...

Melissa Kaltenbach

Melissa Kaltenbach

May 8, 2023
The Why? Series

Why is it recommended to provide reproductive health counseling to women with cirrhosis?

Women with cirrhosis can and do get pregnant! In this post, we will discuss pre-conception counseling for cirrhotic women and how to best manage them throughout their pregnancy. Why is fertility...

Melissa Kaltenbach

Melissa Kaltenbach

January 16, 2023
The Why? Series

Why are non-invasive risk scores such as FIB-4 used in clinical practice?

One of the most important predictors of liver related morbidity and mortality is stage of liver fibrosis. This makes identifying and quantifying the degree of fibrosis extremely important to risk...

Melissa Kaltenbach

Melissa Kaltenbach

February 20, 2022
The Why? Series

Why do we use antibiotics for SBP prophylaxis?

You may have noticed that we often start antibiotics for patients with cirrhosis to prevent spontaneous bacterial peritonitis (SBP). Have you ever wondered why?

Melissa Kaltenbach

Melissa Kaltenbach

August 15, 2021

Subscribe

Enter your email here and receive monthly newsletters with new LFN material.

Registration failed. Please try again later.

Thanks for signing up!

AASLD LFN Logo

Follow Us

Disclaimer & Privacy Policy

© 2025 American Association for the Study of Liver Diseases